Eli Lilly and Purdue University, US, have announced the widening of their existing partnership with a planned investment of ...

Shares in Eli Lilly have weakened after CVS Health, one of the largest pharmacy benefit managers (PBMs) in the US, said it would no longer cover its obesity therapy Zepbound. The shares closed ...

The first reveal of clinical data with Eli Lilly’s injectable triple receptor agonist for obesity suggests that the company could have a big winner on its hands if the drug makes it through to ...